Fertility concerns influence treatment decisions in younger patients with breast cancer
the ONA take:
Previous studies have shown that following a 5-year course of tamoxifen after breast cancer treatment can reduce recurrence by 47% and mortality by 26%.
In addition, more recent data suggests taking tamoxifen for 10 years may be even more beneficial. However, many patients with breast cancer, especially premenopausal women, decline the therapy or discontinue it in less than 5 years.
This study found that 13% of patients declined tamoxifen therapy and 16% stopped before the recommended 5 years of treatment were up.
Phone interviews conducted with 88 patients who did not initiate or discontinued tamoxifen revealed concerns about fertility and side effects were primary factors for these patients’ decision.
The researchers conclude these findings demonstrate a need to include appropriate counseling for patients who express concerns about future fertility at the outset as part of a multidisciplinary treatment plan.
They suggested that a dialog about fertility could identify more patients willing to complete the recommended course if they could delay or take a break from the therapy to allow for pregnancy.
A new international trial, called POSITIVE, being conducted by the International Breast Cancer Study Group, is looking at whether premenopausal women who take a hiatus to become pregnant then resume the therapy would have similar benefit as those who taken tamoxifen continuously for 5 years.
Previous studies have shown that following a 5-year course of tamoxifen after breast cancer treatment can reduce recurrence.
Sign Up for Free e-newsletters
- Triplet Regimen Found Most Effective for Relapsed/Refractory Multiple Myeloma
- Integrating Preoperative Oral Care Into Cancer Treatment Plans
- Current Status and Dilemma of Second-line Treatment in Advanced Pancreatic Cancer: Is There a Silver Lining?
- American Association for Cancer Research Releases Its 2018 Annual Report
- Pulmonary Toxicity Increased in Pediatric Hodgkin Lymphoma Treated With Brentuximab Vedotin
- Benefit of Chemotherapy for Breast Cancer Observed With Midrange Gene Assay Score
- Antioxidant Interaction With Cancer Therapy
- Young Survivors of Breast Cancer Report Sexual Quality of Life Declines After Treatment
- Myeloablative Conditioning Effective in AML Secondary to MDS/MPN Prior to Allogeneic HCT
- Insurance Status Influences Overall Survival in Follicular Lymphoma
- Skin Cancer Screening: Are They Effective?
- Metronidazole, Vancomycin Recommended for C Difficile in Pediatric Oncology, HSCT
- CDC: HPV Vaccination Rates on the Rise Among Adolescents
- High-Dose vs Standard-Dose Flu Vaccine in Elderly Receiving Chemotherapy
- FDA Grants Approval to Novel Treatment for Hairy Cell Leukemia
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|